1
|
Wei X, Zhong Y, Yi X, Li T, Ling Z, Ming M, Zhang S, He Z. Evidence Construction of Chuankezhi Injection Against Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Pharmacology. Int J Chron Obstruct Pulmon Dis 2024; 19:1177-1196. [PMID: 38826697 PMCID: PMC11141582 DOI: 10.2147/copd.s442281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Accepted: 05/20/2024] [Indexed: 06/04/2024] Open
Abstract
Objective Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease with high prevalence, morbidity, and mortality. Chuankezhi (CKZ) injection, a Chinese patent medicine, has been commonly used for treating COPD. This study evaluated the clinical efficacy of CKZ injections in COPD patients and explored potential underlying mechanisms by integrating meta-analysis and network pharmacology. Research Methods Randomized controlled trials (RCTs) were search in database by Web of Science, Cochrane Library and PubMed as of November 2022 for literature collection, and the Review Manager 5.4 was used to analyze the data. Through the network pharmacology method, the chemical components and their targets, as well as the disease targets were further analyzed. Results A total of 15 RCTs including 1212 patients were included. The results of meta-analysis showed that CKZ injection can significantly improve the clinical effective rate (RR = 1.25, 95% CI: 1.14 to 1.36), and the clinical advantage was that it can significantly reduced acute exacerbation rate (RR = 0.29, 95% CI: 0.12 to 0.70) and COPD assessment test (CAT) scores (MD =-4.62, 95% CI:-8.966 to-0.28). A total of 31 chemical compounds and 178 potential targets for CKZ injection were obtained from the online databases. Molecular docking revealed that most key components and targets could form stable structure. Conclusion This systematic review with meta-analysis and network pharmacology demonstrates that CKZ could effectively improve the clinical efficacy and safety in the treatment of COPD. Such efficacy may be related to an anti-inflammatory effect and immunoregulation of CKZ via multiple components, multiple targets and multiple pathways.
Collapse
Affiliation(s)
- Xuan Wei
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China
- Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, People’s Republic of China
| | - Yu Zhong
- Department of Emergency Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, People’s Republic of China
| | - Xiaofei Yi
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China
| | - Tingting Li
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China
| | - Zhougui Ling
- Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, People’s Republic of China
| | - Moyu Ming
- Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, People’s Republic of China
| | - Shuang Zhang
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China
| | - Zhiyi He
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China
| |
Collapse
|
2
|
Qi ZM, Wang X, Liu X, Zhao J. Asperuloside Promotes Apoptosis of Cervical Cancer Cells through Endoplasmic Reticulum Stress-Mitochondrial Pathway. Chin J Integr Med 2024; 30:34-41. [PMID: 37076638 DOI: 10.1007/s11655-023-3695-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/26/2022] [Indexed: 04/21/2023]
Abstract
OBJECTIVE To investigate the effects of asperuloside on cervical cancer based on endoplasmic reticulum (ER) stress and mitochondrial pathway. METHODS Different doses (12.5-800 µg/mL) of asperuloside were used to treat cervical cancer cell lines Hela and CaSki to calculate the half maximal inhibitory concentration (IC50) of asperuloside. The cell proliferation was analyzed by clone formation assay. Cell apoptosis, intracellular reactive oxygen species (ROS) and mitochondrial membrane potential were determined by flow cytometry. The protein expressions of cleaved-caspase-3, Bcl-2, Bax, Cyt-c, cleaved-caspase-4 and glucose-regulated protein 78 (GRP78) were analyzed by Western blot. And the inhibitor of ER stress, 4-phenyl butyric acid (4-PBA) was used to treat cervical cancer cells to further verify the role of ER stress in the apoptosis of cervical cancer cells induced by asperuloside. RESULTS Asperuloside of 325, 650, and 1300 µg/mL significantly inhibited the proliferation and promoted apoptosis of Hela and CaSki cells (P<0.01). All doses of asperuloside significantly increased intracellular ROS levels, reduced mitochondrial membrane potential, significantly reduced Bcl-2 protein expression level, and increased Bax, Cyt-c, GRP78 and cleaved-caspase-4 expressions (P<0.01). In addition, 10 mmol/L 4-PBA treatment significantly promoted cell proliferation and reduced apoptosis (P<0.05), and 650 µg/mL asperuloside could reverse 4-PBA-induced increased cell proliferation, decreased apoptosis and cleaved-caspase-3, -4 and GRP78 protein expressions (P<0.05). CONCLUSION Our study revealed the role of asperuloside in cervical cancer, suggesting that asperuloside promotes apoptosis of cervical cancer cells through ER stress-mitochondrial pathway.
Collapse
Affiliation(s)
- Zhi-Min Qi
- Medical Examination Center, Hebei Province Hospital of Chinese Medicine, Shijiazhuang, 050011, China
| | - Xia Wang
- Department of Gynaecology and Obstetrics, Hebei Province Hospital of Chinese Medicine, Shijiazhuang, 050011, China
| | - Xia Liu
- Department of Gynaecology and Obstetrics, Hebei Province Hospital of Chinese Medicine, Shijiazhuang, 050011, China
| | - Juan Zhao
- Experimental Center for Teaching, Hebei Medical University, Shijiazhuang, 050017, China.
| |
Collapse
|
3
|
Li K, Yu XH, Maskey AR, Musa I, Wang ZZ, Garcia V, Guo A, Yang N, Srivastava K, Dunkin D, Li JX, Guo L, Cheng YC, Yuan H, Tiwari R, Li XM. Cytochrome P450 3A4 suppression by epimedium and active compound kaempferol leads to synergistic anti-inflammatory effect with corticosteroid. Front Pharmacol 2023; 13:1042756. [PMID: 36793921 PMCID: PMC9922998 DOI: 10.3389/fphar.2022.1042756] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 12/23/2022] [Indexed: 01/31/2023] Open
Abstract
Introduction: Cytochrome P450 (CYP) 3A4 is a major drug metabolizing enzyme for corticosteroids (CS). Epimedium has been used for asthma and variety of inflammatory conditions with or without CS. It is unknown whether epimedium has an effect on CYP 3A4 and how it interacts with CS. We sought to determine the effects of epimedium on CYP3A4 and whether it affects the anti-inflammatory function of CS and identify the active compound responsible for this effect. Methods: The effect of epimedium on CYP3A4 activity was evaluated using the Vivid CYP high-throughput screening kit. CYP3A4 mRNA expression was determined in human hepatocyte carcinoma (HepG2) cells with or without epimedium, dexamethasone, rifampin, and ketoconazole. TNF-α levels were determined following co-culture of epimedium with dexamethasone in a murine macrophage cell line (Raw 264.7). Active compound (s) derived from epimedium were tested on IL-8 and TNF-α production with or without corticosteroid, on CYP3A4 function and binding affinity. Results: Epimedium inhibited CYP3A4 activity in a dose-dependent manner. Dexamethasone enhanced the expression of CYP3A4 mRNA, while epimedium inhibited the expression of CYP3A4 mRNA and further suppressed dexamethasone enhancement of CYP3A4 mRNA expression in HepG2 cells (p < 0.05). Epimedium and dexamethasone synergistically suppressed TNF-α production by RAW cells (p < 0.001). Eleven epimedium compounds were screened by TCMSP. Among the compounds identified and tested only kaempferol significantly inhibited IL-8 production in a dose dependent manner without any cell cytotoxicity (p < 0.01). Kaempferol in combination with dexamethasone showed complete elimination of TNF-α production (p < 0.001). Furthermore, kaempferol showed a dose dependent inhibition of CYP3A4 activity. Computer docking analysis showed that kaempferol significantly inhibited the catalytic activity of CYP3A4 with a binding affinity of -44.73kJ/mol. Discussion: Inhibition of CYP3A4 function by epimedium and its active compound kaempferol leads to enhancement of CS anti-inflammatory effect.
Collapse
Affiliation(s)
- Ke Li
- Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Guangzhou University of Chinese Medicine, Foshan, China,Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, United States
| | - Xiu-Hua Yu
- Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, United States,Central Laboratory, Affiliated Hospital, Changchun University of Chinese Medicine, Changchun, China
| | - Anish R. Maskey
- Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, United States
| | - Ibrahim Musa
- Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, United States
| | - Zhen-Zheng Wang
- Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, United States,Academy of Chinese Medical Science, Henan University of Chinese Medicine, Zhengzhou, China
| | - Victor Garcia
- Department of Pharmacology, New York Medical College, Valhalla, NY, United States
| | - Austin Guo
- Department of Pharmacology, New York Medical College, Valhalla, NY, United States
| | - Nan Yang
- Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, United States,General Nutraceutical Technology, Elmsford, NY, United States
| | - Kamal Srivastava
- Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, United States,General Nutraceutical Technology, Elmsford, NY, United States
| | - David Dunkin
- Department of Pediatrics, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Jun-Xiong Li
- Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Guangzhou University of Chinese Medicine, Foshan, China
| | - Longgang Guo
- Guangzhou ImVin Pharmaceutical Co., Ltd., Guangzhou, China
| | - Yung-Chi Cheng
- Department of Pharmacology, School of Medicine, Yale University, New Haven, China
| | - Haoliang Yuan
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
| | - Raj Tiwari
- Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, United States
| | - Xiu-Min Li
- Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, United States,Department of Otolaryngology, Westchester Medical Center New York Medical College, Valhalla, NY, United States,*Correspondence: Xiu-Min Li,
| |
Collapse
|
4
|
Investigation of the Mechanisms of Chuankezhi Injection in the Treatment of Asthma Based on the Network Pharmacology Approach. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2021; 2021:5517041. [PMID: 34221070 PMCID: PMC8213469 DOI: 10.1155/2021/5517041] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Accepted: 06/03/2021] [Indexed: 11/18/2022]
Abstract
Background Chuankezhi injection (CKZI) was an effective traditional Chinese medicine (TCM) injection in adjuvant bronchial asthma therapy. In this report, we used a network pharmacology method to reveal the mechanisms of CKZI for the treatment of asthma. Methods The candidate compounds in CKZI were determined by searching the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and China National Knowledge Infrastructure website (CNKI). The targets of candidate compounds were searched in the TCMSP, DrugBank 5.0, and SwissTargetPrediction. The disease targets were screened from the Online Mendelian Inheritance in Man (OMIM) and GeneCards. The overlapping gene symbols between candidate compounds and disease were filtered via a Venn diagram and were considered as potential targets. A protein-protein interaction (PPI) network and disease-related candidate compound-target-pathway (DC-T-P) network were visualized by Cytoscape 3.6.1. Gene Ontology (GO) functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed by metascape to determine the pathways related to asthma. Results A total of 70 overlapping gene symbols were recognized as potential targets. Cytokines (IL6, TNF, and IL1B) and chemokines (CXCL8 and CCL2) could be recognized as hub genes. Asthma-related candidate compounds were mainly flavonoids, such as quercetin, luteolin, and kaempferol. The cytokine-mediated signaling pathway, cytokine receptor binding, and membrane craft were the most significant biological process (BP), molecular function (MF), and cellular component (CC) of GO function results, respectively. The relevant pathways of CKZI against asthma mainly include IL-17, NF-kappa B, HIF-1, calcium, and PI3K-Akt signaling pathways. Conclusion Our research provided a theoretical basis for further investigating the mechanisms of CKZI in the treatment of asthma.
Collapse
|
5
|
Meng Y, Yu Z, Wu Y, Du T, Chen S, Meng F, Su N, Ma Y, Li X, Sun S, Zhang G. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application. Hum Vaccin Immunother 2017; 13:1-9. [PMID: 28301281 PMCID: PMC5489295 DOI: 10.1080/21645515.2017.1285987] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Revised: 01/11/2017] [Accepted: 01/19/2017] [Indexed: 12/24/2022] Open
Abstract
Cell-based immunotherapy holds promise in the quest for the treatment of cancer, having potential synergy with surgery, chemotherapy and radiotherapy. As a novel approach for adoptive cell-based immunotherapy, cytokine-induced killer (CIK) cells have moved from the 'bench to bedside'. CIK cells are a heterogeneous subset of ex-vitro expanded, polyclonal T-effector cells with both natural killer (NK) and T-cell properties, which present potent non-major histocompatibility complex-restricted cytotoxicity against a variety of tumor target cells. Initial clinical studies on CIK cell therapy have provided encouraging results and revealed synergistic antitumor effects when combined with standard therapeutic procedures. At the same time, issues such as inadequate quality control and quantity of CIK cells as well as exaggerated propaganda were continuously emerging. Thus, the Ministry of Health in China stopped CIK cell therapy in May 2016, which was a major setback for the innovation of CIK cell-based immunotherapy. Thus, it is very important to modify technical criteria to develop a standardized operation procedure (SOP) and standardized system for evaluating antitumor efficacy in a safe way.
Collapse
Affiliation(s)
- Yiming Meng
- Central Laboratory, Cancer Hospital of China Medical University, Dadong District, Shenyang, China
| | - Zhifu Yu
- Department of Epidemiology, Cancer Hospital of China Medical University, Dadong District, Shenyang, China
| | - Yefeng Wu
- Central Laboratory, Cancer Hospital of China Medical University, Dadong District, Shenyang, China
| | - Tianzhao Du
- Central Laboratory, Cancer Hospital of China Medical University, Dadong District, Shenyang, China
| | - Shi Chen
- Central Laboratory, Cancer Hospital of China Medical University, Dadong District, Shenyang, China
| | - Fanjuan Meng
- Central Laboratory, Cancer Hospital of China Medical University, Dadong District, Shenyang, China
| | - Nan Su
- Central Laboratory, Cancer Hospital of China Medical University, Dadong District, Shenyang, China
| | - Yushu Ma
- Central Laboratory, Cancer Hospital of China Medical University, Dadong District, Shenyang, China
| | - Xiaoxi Li
- Central Laboratory, Cancer Hospital of China Medical University, Dadong District, Shenyang, China
| | - Sulan Sun
- Central Laboratory, Cancer Hospital of China Medical University, Dadong District, Shenyang, China
| | - Guirong Zhang
- Central Laboratory, Cancer Hospital of China Medical University, Dadong District, Shenyang, China
| |
Collapse
|
6
|
Zhang L, Zhang H, Zhu Z, Jiang L, Lu X, Zhou M, Sun X, He L, Bai Y, Ma L. Matrine regulates immune functions to inhibit the proliferation of leukemic cells. Int J Clin Exp Med 2015; 8:5591-5600. [PMID: 26131142 PMCID: PMC4484016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Accepted: 02/11/2015] [Indexed: 06/04/2023]
Abstract
AIMS To investigate the roles of matrine in regulating immune functions and its effect on the proliferation of leukemic cells. METHODS Human leukemia K562, OUN-1, HL-60, U937, K562/AO2 cell lines and primary leukemic cells were used to detect the NKG2D ligands (NKG2DL) expression such as MICA/B, ULBP-1, ULBP-2, ULBP-3, and NK cells receptor NKG2D, CD158a, CD158b were detected by flow cytometry. Cell cytotoxic activity of human NK cells and CIK cells against K562 leukemia cells was detected using CFSE/PI double staining. Pro-inflammatory cytokines and adhesion molecules in K562 or NK cells supernatant after matrine treatment were detected. RESULTS Matrine could upregulate the expression of NKG2DL on leukemic cell lines, and primary leukemic cells and enhance the NK and CIK cytotoxicity targeted to K562 cells. After matrine treatment, pro-inflammatory cytokines and adhesion molecular such as IL-6, IL-1, IL-2, IL-4, IL-5, GRO and TNF-α in K562 cells supernatant were significantly decreased (P < 0.05). Flow cytometry analysis showed that the NKG2D expression was up-regulated significantly as well as the CD158a and CD158b expression decreased after treatment with different concentration of matrine in a dose-dependent manner in K562 cells. A significant decrease of supernatant concentrations of IL-1α, IL-5, IL-6, IL-10, IFN-γ, GRO and TNF-α in NK cells was also observed after exposure to the matrine. CONCLUSION Matrine regulates immune functions to inhibit the proliferation of leukemic cells.
Collapse
Affiliation(s)
- Lei Zhang
- Department of Advanced Medical Service, Tongji Hospital, Tongji UniversityShanghai 200065, China
| | - Huizhang Zhang
- Department of Laboratory Medicine, Jinshan Hospital, Fudan UniversityShanghai 201508, China
| | - Zhichao Zhu
- Laboratary Center, Changzhou No. 2 People’s Hospital, The Affiliated Hospital of Nanjing Medical UniversityChangzhou 213000, China
| | - Lijia Jiang
- Laboratary Center, Changzhou No. 2 People’s Hospital, The Affiliated Hospital of Nanjing Medical UniversityChangzhou 213000, China
| | - Xuzhang Lu
- Department of Hematology, Changzhou No. 2 People’s Hospital, The Affiliated Hospital of Nanjing Medical UniversityChangzhou 213000, China
| | - Min Zhou
- Department of Hematology, Changzhou No. 2 People’s Hospital, The Affiliated Hospital of Nanjing Medical UniversityChangzhou 213000, China
| | - Xiao Sun
- Laboratary Center, Changzhou No. 2 People’s Hospital, The Affiliated Hospital of Nanjing Medical UniversityChangzhou 213000, China
| | - Liuyang He
- Laboratary Center, Changzhou No. 2 People’s Hospital, The Affiliated Hospital of Nanjing Medical UniversityChangzhou 213000, China
| | - Yu Bai
- Laboratary Center, Changzhou No. 2 People’s Hospital, The Affiliated Hospital of Nanjing Medical UniversityChangzhou 213000, China
| | - Lingdi Ma
- Laboratary Center, Changzhou No. 2 People’s Hospital, The Affiliated Hospital of Nanjing Medical UniversityChangzhou 213000, China
| |
Collapse
|